# A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia

> **NCT01124617** · PHASE2 · COMPLETED · sponsor: **Janssen Pharmaceutical K.K.** · enrollment: 91 (actual)

## Conditions studied

- Pain
- Diabetic Neuropathies
- Neuralgia
- Postherpetic Neuralgia

## Interventions

- **DRUG:** Tapentadol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01124617
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2014-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01124617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01124617, "A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01124617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*